Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Drug Delivery Systems - September 19, 2017

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 107     Next >>     Go To Page:

9/19/17 - Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis. The Company recently began a Phase 2 clinical study, the CENTAUR trial, to evaluate the safety and efficacy of AMX003
9/19/17 - Bayer receives FDA approval for Copanlisib in adults with relapsed follicular lymphoma after two prior systemic therapies
Release date- 18092017- Berlin- Bayer announced today that the U.S. Food and Drug Administration has approved copanlisib under the brand name Aliqopa 60 mg vial for injection for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The FDA granted approval under the accelerated a
9/19/17 - BD Introduces New 6mm Pen Needle for Injection Pens
FRANLIN LAKES, N.J., Sept. 19, 2017/ PRNewswire/ BD, a leading global medical technology company, today announced the introduction of the BD Ultra-Fine? micro pen needle 6 mm x 32 G for use with leading pen injection devices, that is set for distribution starting September 2017. The introduction of the new pen needle rounds out the BD Ultra-Fin
9/19/17 - Beximco Pharma commences export to Canada
Release date- 17092017- Beximco Pharmaceuticals Limited, the fast growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada. According to IMS data, the current market size for...
9/19/17 - Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.
Ketorolac Tromethamine Injection has been developed in collaboration with Caplin Point Laboratories Ltd and is manufactured at their FDA approved site. After the successful launch of Nityr? tablets last month from our Orphan Drugs Division, we are proud to be announcing the first product from our Generics Division. said Steve Fuller, Head o
9/19/17 - Global Lyophilized Injectable Drugs Market, 2017-2024
The "Lyophilized Injectable Drugs to 2024" report has been added to Research and Markets' offering.. The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices that allow reconstitution to take
9/19/17 - Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Lipocine Inc., a specialty pharmaceutical company, announced today that Dr. Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by...
9/19/17 - Lyophilized Injectable Drugs Market, 2024 - Research and Markets
The "Lyophilized Injectable Drugs to 2024" report has been added to Research and Markets' offering. The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture un
9/19/17 - Mayne Pharma adds two products to its Australian portfolio
Release date- 18092017- Mayne Pharma Group Limited is pleased to announce it has received TGA approval for Monurol granules and has recently launched Urorec capsules in Australia. Both products are new chemical entity approvals from the TGA, and the first two approvals of this kind by Mayne Pharma. Mayne Pharma licensed the Australian rights to Mon
9/19/17 - Medtronic Announces FDA Approval and U.S. Launch of Next Generation Spinal Cord Stimulator for Chronic Pain Management [Algeria Press Service]
DUBLIN- September 18, 2017- Medtronic plc today announced FDA approval and U.S. launch of the Intellis (TM) platform for the management of certain types of chronic intractable pain. The Intellis platform can record and track patient activity 24/ 7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subje
9/19/17 - Medtronic Announces FDA Approval, U.S. Launch of Next Generation Spinal Cord Stimulator for Chronic Pain Management
Medtronic issued the following news release:. Medtronic plc today announced FDA approval and U.S. launch of the Intellis (TM) platform for the management of certain types of chronic intractable pain. The Intellis platform can record and track patient activity 24/ 7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to
9/19/17 - Medtronic rolls out latest device to treat pain with electricity [Star Tribune (Minneapolis)]
Sept. 19 With medical device companies across the nation hustling to find ways to treat pain without addictive opioid drugs, Medtronic is launching a system called the Intellis that uses electricity and can be securely controlled with a Samsung tablet. Marshall Stanton, president of Medtronic's pain therapies division, said in a news release.
9/19/17 - Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets
Release date- 18092017- HERTFORDSHIRE, England and PITTSBURGH- Mylan N.V., today announced the U.S. launch of Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tablets, 1 mg/20 mcg, which is indicated for use by women to prevent pregnancy. Norethindrone Acetate and Ethinyl Estradiol Tablets USP, and Ferrous Fumarate Tabl
9/19/17 - Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER Extended Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
Release date- 18092017- DALLAS and FORT WORTH- Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended release products using its proprietary modified release drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved Adzenys ER Extended.
9/19/17 - Pivot Pharma Looks to Improve Cannabinoid Bioavailability with Topical BiPhasix(TM) Delivery System CFN Media
CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining Pivot Pharmaceuticals Inc. and its recent acquisition of the BiPhasix? Transdermal Drug Delivery technology for the delivery of cannabinoids. Pivot Pharmaceuticals recognized the benefits of...
9/19/17 - Researchers from Yeungnam University Report Recent Findings in Drug Delivery Systems (Multiple polysaccharide-drug complex-loaded liposomes: A unique...
By a News Reporter-Staff News Editor at Cancer Weekly Research findings on Drugs and Therapies- Drug Delivery Systems are discussed in a new report. According to news reporting out of Gyongsan, South Korea, by NewsRx editors, research stated, "In the present study, a unique strategy was developed to develop nanocarriers containing multiple therap
9/19/17 - Seqirus Receives FDA Approval of AFLURIA QUADRIVALENT for People Five Years of Age and Older in the U.S
AFLURIA QUADRIVALENT, which was first approved in the U.S. in August 2016 for people aged 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.3, 10. The U.S. Centers for Disease Control and Prevention recommends annual influenza vaccination for everyone six months of age and older.6 Recently, the CDC' s Advis
9/19/17 - Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States
JERUSALEM& SAN FRANCISCO Teva Pharmaceutical Industries Ltd. and Nuvelution Pharma, Inc. today announced their partnership to develop AUSTEDO tablets for the treatment of tics associated with Tourette syndrome in pediatric patients in the United States. Upon FDA approval of AUSTEDO in TS, Teva will pay Nuvelution a pre-agreed return on it
9/19/17 - Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
Theravance Biopharma, Inc. today highlighted that the US Food and Drug Administration has approved Trelegy Ellipta, the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA inhaler, for the long-term, once-daily, maintenance treatment of appropriate patients with chronic obstructive pulmonary dise
9/19/17 - Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference
Theravance Biopharma, Inc. announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under t
9/19/17 - U.S. FDA Grants Fast Track Designation for Amicus Therapeutics Migalastat for Treatment of Fabry Disease
Amicus Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for the oral precision medicine migalastat for the treatment of patients with Fabry disease with amenable mutations. This Fast Track designation recognizes that Fabry is a serious disease and that migalastat has the potential to address
9/19/17 - Ultimate Analysis on Auto-Injectors Market: Valuation USD 2.4 billion by 2022, at a CAGR of ~17.2%
Global Auto-Injectors Market Information, By Product Type, By Application, By Suppliers- Forecast Till 2022. Market Research Future published a research report on "Auto-Injectors Market Research Report- Global Forecast to 2022"- Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.. Market Synopsis of Global Auto-Injectors Market:.
9/19/17 - Wearable Injectors Market Set to Witness an Uptick During 2017-2025
The global market for wearable injectors is primarily driven by the advantage offered by wearable injectors in terms of large volume subcutaneous delivery of drugs.San Francisco, CA 09/18/2017 Global Wearable Injectors Market: OverviewWearable injectors are devices that are designed to administer large volume subcutaneous delivery of drugs ov
9/19/17 - World Transdermal Drug Delivery Technologies, Markets, and Companies Forecasts to 2026 - Research and Markets
The "Transdermal Drug Delivery- Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering. This report deals with transdermal drug delivery- an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral, intravascular, subcutaneous and transmucosal routes
9/18/17 - AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA?/VENCLYXTO? (Venetoclax) Tablets in Combination with Rituxan (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
AbbVie, a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of VENCLEXTA?/ VENCLYXTO? Tablets in combination with Rituxan met its primary endpoint. Doctors will continue to monitor patients who remain active in the MURANO trial in efforts to obtain additional, longer-term safety
Articles(s): 1 - 25 of 107     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415